Lantern Pharma Inc Cash Flow Conversion Efficiency
Lantern Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Lantern Pharma Inc (LTRN) has a cash flow conversion efficiency ratio of 0.914x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.94 Million) by net assets ($-3.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lantern Pharma Inc (2018–2025)
Cash flow conversion efficiency of Lantern Pharma Inc from 2018 to 2025. This chart illustrates how Lantern Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Lantern Pharma Inc stock quote for real-time trading data and today's change.
Lantern Pharma Inc Cash Flow Conversion Ratio Explained
Lantern Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lantern Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lantern Pharma Inc ranked by their cash flow conversion efficiency. Also see market value of Lantern Pharma Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Infimer Ltd
TA:INFR
|
0.002x |
|
Talisman Mining Ltd
F:RJA
|
0.028x |
|
Birks Group Inc
NYSE MKT:BGI
|
0.210x |
|
RAREX Ltd
AU:REE
|
-0.479x |
|
Orcoda Ltd
AU:ODA
|
-0.059x |
|
Fatfish Group Ltd
AU:FFG
|
0.106x |
|
Imperial Pacific Ltd
AU:IPC
|
0.024x |
|
Solo Brands, Inc.
NYSE:SBDS
|
-0.347x |
Annual Cash Flow Conversion Efficiency for Lantern Pharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lantern Pharma Inc from 2018 to 2025. Review Lantern Pharma Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.53 Million | $-15.68 Million | -2.399x | -185.37% |
| 2024-12-31 | $21.19 Million | $-17.81 Million | -0.841x | -139.73% |
| 2023-12-31 | $40.91 Million | $-14.35 Million | -0.351x | -53.93% |
| 2022-12-31 | $56.04 Million | $-12.77 Million | -0.228x | -53.96% |
| 2021-12-31 | $71.57 Million | $-10.59 Million | -0.148x | +48.42% |
| 2020-12-31 | $19.70 Million | $-5.65 Million | -0.287x | +87.28% |
| 2019-12-31 | $943.28K | $-2.13 Million | -2.256x | -135.80% |
| 2018-12-31 | $-201.80K | $-1.27 Million | 6.301x | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more